The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
The deal signals a clear push to expand access to care in underserved regions
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
The summit brought together over 150 doctors, researchers, and practitioners worldwide
Multi-stakeholder initiative highlights inclusive sports pathways, honours neurodivergent athletes, and calls for systemic reforms
Subscribe To Our Newsletter & Stay Updated
